Temporal Concept
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials
FDA Advisors Back Zevra’s Rare Disease Medication Based on Clinical Intuition
Zevra Therapeutics, FDA advisory committee, rare disease medication, clinical intuition, potential approval
Biopharma Companies uniQure and Arbutus Announce Workforce Reductions to Focus on Priority Programs
uniQure, Arbutus Biopharma, layoffs, workforce reduction, biopharma, priority programs, gene therapy, clinical trials
Eisai’s Alzheimer’s Drug Leqembi Shows Long-Term Benefits, Despite Study Limitations
Eisai, Leqembi, Alzheimer’s drug, long-term benefits, study limitations, cognitive decline, amyloid plaques, Biogen
GSK Abandons Phase 2 HPV Vaccine Due to Lack of Best-in-Class Potential
GSK, HPV vaccine, phase 2, best-in-class potential, vaccine development
Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials
Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer
FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC
AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy
FDA Advisers Call for Revamp of Perioperative Lung Cancer Trials Due to Frustration with AstraZeneca’s Imfinzi Design
FDA, Imfinzi, AstraZeneca, perioperative lung cancer trials, revamp, design issues
Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff
Biopharma, Layoffs, 2024, Anokion, GlycoMimetics, Relay, Restructuring, Job Cuts, Industry Trends
SEC Staff Recommends Enforcement Action Against Allarity Over Potential Federal Securities Laws Violations
Allarity Therapeutics, SEC, Enforcement Action, Federal Securities Laws, Violations, Wells Notice, FDA, Dovitinib, Stenoparib